SCHEMBL176415

SCHEMBL176415

CCO[Si](OCC)(OCC)C(CC)OC(=O)CCC(=O)OC(CC)[Si](OCC)(OCC)OCC

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.33
TSHR P16473 2/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
MAPK1 P28482 1/20 0.32
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA3 P07451 1/20 0.31
CA4 P22748 1/20 0.31
CA6 P23280 1/20 0.31
CA5A P35218 1/20 0.31
CA7 P43166 1/20 0.31
CA9 Q16790 1/20 0.31
CA13 Q8N1Q1 1/20 0.31
CA14 Q9ULX7 1/20 0.31
CA5B Q9Y2D0 1/20 0.31
ALDH1A1 P00352 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL176418 0.93 EGLN1 (0.36) LMNA
SCHEMBL6267404 0.92 ALDH1A1 (0.40) LMNAMAPTMAPK1ALDH1A1
SCHEMBL8839158 0.89 LMNA (0.44) LMNATSHRMAPTMAPK1ALDH1A1
SCHEMBL9323704 0.88 MGAM (0.38)
SCHEMBL8839122 0.88 MEN1 (0.33)
SCHEMBL8839181 0.86 LMNA (0.54) LMNATSHRMAPTMAPK1ALDH1A1
SCHEMBL8839276 0.86 LMNA (0.54) LMNATSHRMAPTMAPK1ALDH1A1
SCHEMBL8839107 0.86 LMNA (0.54) LMNATSHRMAPTMAPK1ALDH1A1
SCHEMBL1070487 0.83 MGAM (0.39)
SCHEMBL9323718 0.83 MGAM (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551332-B2 Affinity particle and affinity separation method SHISEIDO COMPANY, LTD. (JP) 2013-10-08 US disclosed
EP-1759761-B1 AFFINITY PARTICLE AND AFFINITY SEPARATION METHOD SHISEIDO CO LTD (JP) 2011-07-27 EP disclosed
EP-1750127-B1 Method of affinity separation. SHISEIDO CO LTD (JP) 2011-07-20 EP disclosed
US-20100137133-A1 Affinity Particle And Affinity Separation Method SHISEIDO COMPANY, LTD. (JP) 2010-06-03 US disclosed
US-20090321357-A1 Affinity Particle And Affinity Separation Method SHISEIDO COMPANY, LTD. (JP) 2009-12-31 US disclosed
US-20090321358-A1 Affinity Particle And Method Of Affinity Separation SHISEIDO COMPANY, LTD. (JP) 2009-12-31 US disclosed
US-20070241054-A1 Affinity Particle And Method Of Affinity Separation SHISEIDO COMPANY, LTD. (JP) 2007-10-18 US disclosed
US-20070181503-A1 Affinity particle and affinity separation method SHISEIDO COMPANY, LTD. (JP) 2007-08-09 US disclosed
EP-1759761-A1 AFFINITY PARTICLE AND AFFINITY SEPARATION METHOD SHISEIDO COMPANY, LTD. (JP) 2007-03-07 EP disclosed
EP-1750127-A1 AFFINITY PARTICLE AND METHOD OF AFFINITY SEPARATION Shiseido Company, Limited (JP) 2007-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090321357-A1 Affinity Particle And Affinity Separation Method FCGR1A, ACP1, FCGR3B LMNA 3292/4885TSHR 1965/4885POLB 3060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.